

Intellectual Property advocacy in the fields of:

- IP Infrastructure
- IP Valuation
- M & A
- IP Policy
- Technology Transfer
- Innovation Research
- Patent Law
- Licensing
- Data Management
- Copyright
- Collaborations
- Balance for Rights & Obligations

Private Circulation Only



EDITORIAL...

A much awaited event has dawned upon us. A new era has emerged before us with CIPLA, the pioneer of Indian Pharmaceutical Industry collaborating with the CDRI(Central Drug Research Institute)of CSIR for developing new drugs and medicines for global marketing. *Contd...*

A report on the agreement dated December 24, 2019 is reproduced below.

CDRI & Indian pharma giant Cipla partner to develop new drugs, medicines for global markets

New Delhi: The Council of Scientific and Industrial Research (CSIR) Central Drug Research Institute (CDRI) has signed an agreement for collaboration to jointly develop new drugs for treating various medical conditions and repurposing of drugs for India and global markets with Indian pharmaceutical giant Cipla Ltd.

"This is a great moment for CSIR-CDRI, the premiere drug development and research institute of the country to establish collaboration for the affordable healthcare programme and repurposing of drugs not only for India but also for the global markets in collaboration and active participation from Cipla. In my view, this is one of the unique efforts of a government institution and of a pharmaceutical industry which de novo generated from this soil and spread all over the world for the affordable healthcare for human beings," said Dr Tapas K Kundu, Director, CDRI.

Dr YK Hamied from Cipla said, "Cipla's association with CSIR and CDRI has been ongoing since 1942, and Cipla has benefited over the years from the expertise developed at the labs of CDRI and IICT. Two stalwarts of the CSIR with whom Cipla has been closely associated in the past have been Dr NityaAnand and Dr AV Rama Rao. Now, Cipla and CDRI are embarking on a futuristic programme under the auspices of CSIR for the development of newer drugs not only for India but globally. Hopefully the results of this collaboration will be forthcoming soon. This is an outstanding example between public and private partnership for research and development, leading to the country's progress."



CDRI and Cipla have earlier worked together for new drug discovery purpose. In 1995, a chandonium iodide drug used against neuro muscular blockers, and gugulipid drug for hypolipidemic are some of the drugs developed under one such venture.


Contd...

Cipla has been the pioneer flagship pharmaceutical company of India. Dr. Yusuf Hamied who took over the mantle of CIPLA in early eighties, has ever since brought new visionary vitality under his leadership. In the shortest time frame, CIPLA received global recognition for CIPLA's (and more personally Dr. Yusuf Hamied's) fight against HIV/AIDS. "Fire in the Blood", an international movie on Dr. Yusuf's crusade to make Anti-HIV treatment affordable and available globally, especially for weaker sections and nations, has received global recognition and has led to many awards and accolades being conferred on Dr. Yusuf Hamied. Now, there is one more crown being placed on CIPLA and Dr. Yusuf Hamied's visionary leadership.

CDRI (Central Drug Research Institute) has also been a pioneer in the early days of India's break through into self-reliance in pharmaceuticals, commencing in the seventies. Many stalwarts headed the CDRI, leading among them being Dr. NityaAnand. NCE launched by DRI, "Centchroman" provides the proof of its brilliance of CDRI.

While "PPP (Public Private Partnership)" and "Industry-Academia Collaboration" has more or less remained slogans and public posturing, it is heartening to see this report, reproduced herein, about CIPLA and CDRI coming together for providing the much-needed impetus to drug research in India, especially New Drug Research. NCEs from India, is a great initiative in the true spirit of the New Year, the "20-20" year, moving out from the "teens" of Indian Pharma Research. We, CIPROM and myself personally, Dr. Gopakumar G. Nair, have great pleasure to congratulate Dr. Yusuf Hamied and the entire CIPLA Team as well as CDRI Team for coming together to make longer, deeper and faster strides into the realm of intensive, inventive, investigational research leading to break-through innovations.

In this context, setting up a more binding research partnership between CDRI and a reputed pharmaceutical company like CIPLA with a mutually binding longterm agreement and legally vetted collaboration document is called for in the best interests of the Indian Pharma Research and global leadership in Innovation and NCE in coming years.



NEWS SNIPPETS

- ❖ **The Department of Promotion of Industry and Internal Trade DPIIT) has issued an advertisement for the post of Vice-Chairman at the IPAB through the Patent Office website.**

Application form is available on the following link.

<https://dipp.gov.in/jobs/appointment-post-vice-chairman-ipab>

- ❖ **The Supreme Court has extended the service term of Justice Manmohan Singh, Chairman of the Intellectual Property Appellate Board (IPAB).**

The order is available on the link below.

https://images.assettype.com/barandbench/2019-12/829f572d-5ff5-421d-8a2b-a10cc8d07727/Supreme_Court___IPAB_Chairman_Order.pdf

- ❖ **Justice PRATHIBA M. SINGH of Delhi High Court, in a landmark judgment on Post-Grant Opposition procedure** related proceedings, has come out with guidelines for filing documents and evidence under Rule 59 to 62 of the Patent Rules, 2003.

The Hon'ble Judge has analyzed the provisions in detail and has concluded that additional evidence can be filed with leave of controller and, after making copies of documents available to the parties in opposition provided time is available prior to the next hearing date. Further, it was held that no further filing of evidence is permissible after the first notice of hearing is issued.

For details of the proceedings and the judgment, please refer to the link below.

<http://164.100.68.118/jupload/dhc/PMS/judgement/16-12-2019/PMS20112019CW121052019.pdf>



Goa – Center for Excellence in Intellectual Property [G-CEIP]

Gaining Traction and Setting Tracks: CAMPAIGN 2020 AND BEYOND !!

GOA – CENTER FOR EXCELLENCE IN INTELLECTUAL PROPERTY [G-CEIP]

In keeping with the current scenario with respect to IP considerations, there is a growing need for establishing a **Center for Excellence in Intellectual Property**– *the first of its kind* – in India. Such a center should focus on addressing the immediate need(s) focusing on IP considerations with an appropriate balance of academic training, continuous updating and upgradation of knowledgebase in IP matters and providing IP services to the industry in India with an objective to provide such services globally. The **Goa – Center for Excellence in Intellectual Property [G-CEIP] was established in 2016** with the vision: *“To recognize and protect scientific discovery with the rights it deserves”*The G-CEIP is committed to operate, function and deliver on its commitments to all its stakeholders (academia, industry, scientific community and generators of new knowledge) guided by this vision. The mission of the center is: *“To provide professional services with the highest quality and integrity to scientific community in recognizing and protecting scientific discovery through intellectual property rights at the highest level that it deserves globally”*



Umesh Banakar, PhD
Professor and Founder
Goa-Center for Excellence in
Intellectual Property [G-CEIP]
ipexcelcr@gmail.com

The Objectives of G-CEIP, aligned with its Vision and Mission, focus on a judicious balance of **academic advancement (programs)** through Professional Advancement Programs, **continuous update and upgradation** of knowledgebase in IP matters through various formats and **provide IP services** to the industry in India with an objective to provide such services globally.

G-CEIP focuses on accomplishing the objectives through:

- **Certificate Professional Advancement Programs (CPAP) - courses of varying duration.**
- **Annual IP Conference (National and International) –**

As of date, **G-CEIP in association with the Goa College of Pharmacy [GCP]** has organized four Annual International Conferences, as a first step in many, to introduce the recent advances related to various aspects of IP from generation to preservation and protection. Global experts in IP are invited annually to share their rich and extensive experience in IP matters. These conferences are designed to not only to listen to these experts in IP, but also to facilitate one-on-one interactions with them to enrich the delegates for their professional development.





A very Happy New Year from our CIPROM and GNANLex Team



Dr. Gopakumar G. Nair Addressing The Audience On “Protecting Your Intellectual Property In India” At The 2019 Think Global Conference Held At The Indian International Center, Delhi On 11- 12th December 2019.



Picnic to Matheran Valley School